The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Abstract
Background/aims To assess the risk of hepatic and extrahepatic malignancies in a large cohort of Swedish primary sclerosing cholangitis (PSC) patients compared with that of the general Swedish population.Methods The study cohort comprised 604 PSC patients identified between 1970 and 1998. Follow-up was provided through linkages to the Swedish Cancer and Death registries. Cumulative incidence of malignancies and standard incidence ratio were calculated with the incidence rates in the Swedish population, taking into account: sex, age and calendar year as comparison group.Results Median time of follow-up was 5.7 years (range 0-27.8). Seventy-nine percent had concomitant inflammatory bowel disease. The cause of death was cancer in 44%. The frequency of hepatobiliary malignancies was 13.3% (81/604). Thirty-seven percent (30/81) of all hepatobiliary malignancies were diagnosed less than 1 year after the diagnosis of PSC. The risk for hepatobiliary malignancy was increased 161 times, for colorectal carcinoma 10 times and for pancreatic carcinoma 14 times, compared with that of the general population.Conclusions In this national-based study including the largest cohort of PSC patients ever presented, the frequency of cholangiocarcinoma is 13%. The risk of hepatobiliary carcinoma is constant after the first year after PSC diagnosis with an incidence rate of 1.5% per year. The risk of pancreatic carcinoma is increased 14 times compared with the general Swedish population. These results are suggestive of an increased risk of pancreatic carcinoma in patients with PSC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An important feature of PSC is the inherent risk of neoplasia at the affected mucosal surfaces, most commonly in the form of cholangiocarcinoma (CCA) and colorectal cancer.[5][6][7]”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [5]
In the citing paper
“People with PSC are at increased risk of developing hepatobiliary cancer, particularly CCA, for which the risk is increased 161-398-fold compared to that in the general population.5,7,285,286”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [5]
In the citing paper
“CCA is the most common cause of death in PSC.5,7,287”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [5]
Citations
Cites
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819
Self-citationClinical Patterns in Crohn's Disease: A Statistical Study of 615 Cases
Farmer, R. G., Hawk, W. A., & Turnbull, R. B. (1975) · Gastroenterology · doi:10.1016/s0016-5085(75)80270-8 · Cited by 699
Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis
Wiesner, R. H., Grambsch, P. M., Dickson, R. E., Ludwig, J., Maccarty, R. L., Hunter, E. B., Fleming, T. R., Fisher, L. D., Beaver, S. J., & Larusso, N. F. (1989) · Hepatology · doi:10.1002/hep.1840100406 · Cited by 643
K. M. BOBERG, E. A. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529850166284 · Cited by 517
Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
Broomé, U., Löfberg, R., Veress, B., & Eriksson, L. S. (1995) · Hepatology · doi:10.1002/hep.1840220511 · Cited by 481
Self-citationPrevalence of Primary Sclerosing Cholangitis in Patients With Ulcerative Colitis
Olsson, R., Danielsson, Å., Järnerot, G., Lindström, E., Lööf, L., Rolny, P., Rydén, B.-O., Tysk, C., & Wallerstedt, S. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)70019-t · Cited by 426
Self-citationCholangiocarcinoma Complicating Primary Sclerosing Cholangitis
ROSEN, C. B., NAGORNEY, D. M., WIESNER, R. H., COFFEY, R. J., & LARUSSO, N. F. (1991) · Annals of Surgery · doi:10.1097/00000658-199101000-00004 · Cited by 391
Brentnall, T., Haggitt, R., Rabinovitch, P., Kimmey, M., Bronner, M., Levine, D., Kowdley, K., Stevens, A., Crispin, D., Emond, M., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8566577 · Cited by 337
Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
Chalasani, N., Baluyut, A., Ismail, A., Zaman, A., Sood, G., Ghalib, R., McCashland, T. M., Reddy, R. K., Zervos, X., Anbari, M. A., et al. (2000) · Hepatology · doi:10.1002/hep.510310103 · Cited by 336
Marchesa, P., Lashner, B. A., Lavery, I. C., Milsom, J. W., Hull, T. L., Strong, S. A., Church, J. M., Navarro, G., & Fazio, V. W. (1997) · PubMed · Cited by 329
Research works printed but not linked: 1
- Kornfelt, 1997, Is there an excess risk for colorectal cancer in ulcerative colitis patients with primary sclerosing cholangitis? A population-based study, Gut, 41, 518
Cited by
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Rogler, G., Singh, A., Kavanaugh, A., & Rubin, D. T. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.042 · Cited by 869
Metadata
- Authors
- Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., Almer, S., Granath, F., & Broomé, U.
- Affiliations
- Karolinska Institutet (SE)
- Karolinska University Hospital (SE)
- Sahlgrenska University Hospital (SE)
- Stockholm South General Hospital (SE)
- Uppsala University Hospital (SE)
- University Hospital of Umeå (SE)
- Skåne University Hospital (SE)
- Linköping University Hospital (SE)
- Corresponding author
- Bergquist, Annika
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 36
- Issue
- 3
- Pages
- 321-327
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2006412887
- Cited by
- 717
- References
- 33
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 21 · 2023: 20 · 2022: 31 · 2021: 34 · 2020: 32 · 2019: 38 · 2018: 28 · 2017: 44 · 2016: 40 · 2015: 44 · 2014: 39 · 2013: 39 · 2012: 42
- FWCI
- 9.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Karolinska Institutet
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- primary sclerosing cholangitis, hepatobiliary malignancies, cholangiocarcinoma, pancreatic cancer, colorectal cancer, cancer risk, inflammatory bowel disease, cumulative incidence
- MeSH terms
- Adult, Autopsy, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Pancreatic Neoplasms, Risk Factors, Sweden, Colorectal Neoplasms, Cholangitis, Sclerosing, Incidence, Liver Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1016/s0168-8278(01)00288-4
- The paper
- Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., Almer, S., Granath, F., & Broomé, U. (2002). Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(01)00288-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.